Heart Eye is set to unveil the world’s first AI-powered cardiovascular screening technology using retinal imaging, delivering patients’ cardiovascular disease risk results in just 3 minutes.
Dr.Noon CVD, the groundbreaking product being launched in the UK by Dr Husain Khaki, will debut at two major optical conferences: 100% Optical at ExCeL London and the Optix Conference 2025 at Celtic Manor.
This non-invasive, AI-driven solution marks a major advancement in cardiovascular disease (CVD) risk assessment. By analysing retinal vessel images with advanced artificial intelligence, Dr.Noon CVD autonomously predicts future cardiovascular risks, providing real-time scores without blood sampling or radiation.
“Cardiovascular disease is one of the biggest health challenges we face today,” said Dr. Husain Khaki. “This AI solution is a real breakthrough, making it easier for people to get an early, accurate diagnosis without any invasive procedures.”
He continued: “The fact that results are available in just three minutes is a game-changer for opticians, hospitals, and primary care providers. It means they can act quickly with preventative care, which leads to better outcomes for patients.”
The retinal-based AI tool is capable of assessing cardiovascular risk with the same accuracy as heart CT scans. Unlike traditional diagnostics, such as heart CT scans or carotid ultrasounds, it offers a fast, affordable and safe alternative. Patients avoid blood tests and radiation exposure, while clinicians receive accurate results in minutes. In the future, the technology will also be capable of performing non-invasive assessments for other organs including kidney function.
Conventional heart CT scans expose patients to high-dose radiation and are confined to secondary care, come with high costs, and deliver slow results. Carotid ultrasounds are time-consuming, less precise, and more expensive than retinal imaging. Dr.Noon CVD’s deep-learning algorithm enhances CVD risk stratification, validated on a global cohort, and matches the predictive performance of heart CT scans. Its scalable, cost-effective design enables broader access to life-saving diagnostics.
“Traditional methods like heart CT scans come with a lot of drawbacks for mass screening including high radiation doses, long wait times and expensive costs. This technology helps lower healthcare costs by catching potential issues early and preventing strokes and heart disease before they become serious,” added Dr. Khaki.
“It’s easy to use in hospitals, opticians and primary care settings, giving patients a quick, non-invasive and radiation-free way to get results. DrNoon CVD solves the problem of late diagnoses and makes it easier for more people to access the care they need – ultimately changing the way we approach cardiovascular health around the world.”
Heart Eye will be offering free cardiovascular disease risk retinal scans using Dr.Noon CVD at the following exhibitions:
• 100% Optical: 1-3 March 2025 at London’s ExCeL
• Optix Conference: 17-19 March 2025 at The Celtic Manor.
